98%
921
2 minutes
20
Developing a promising on-demand controllable microneedle drug delivery system could provide stronger self-control and precision delivery of a large payload capacity. Nevertheless, the efficacy of existing systems has been constrained by limitations in the therapeutic payload capacity and slow diffusion of molecules, as well as the necessity for external resource configurations. Drawing inspiration from the multidimensional biomimetic strategies observed in the material properties and functional mechanisms of the bombardier beetle's defensive secretion system, a battery-free and self-propelled biomimetic microneedle system (BSBMs) is proposed for improving therapeutic outcomes and enabling controlled, on-demand drug delivery. The self-powered microneedle delivery platform fully emulates the structure and spray mechanism of bombardier, employing Pt nanoparticles and HO loaded in the reaction chamber, as a built-in fuel source for active and controllable payload delivery. The robust bionic gas injector can serve as an active engine, facilitating the effective permeation of drugs through hollow microneedles without a complex pumping system. This BSBMs triggers the HO decomposition reaction through thumb pressure, generating O pressure as an endogenous driving force to achieve transdermally precise and on-demand drug delivery. The pharmacokinetics of drug release from the BSBMs were evaluated in vivo by quantifying the levels of levonorgestrel (LNG). This active delivery system maintains in vivo LNG concentrations within the therapeutic window range, greatly enhancing on-demand, controlled, and stable drug delivery. This versatile and efficient self-propelled bionic microneedle delivery technology holds substantial promise for a broad spectrum of transdermal therapeutic applications, offering a simplified, convenient, and improved method of administration.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174333 | PMC |
http://dx.doi.org/10.1038/s41378-025-00970-y | DOI Listing |
JAMA Cardiol
September 2025
Department of Medicine, Cardiovascular Medicine, Stanford University, Stanford, California.
Importance: Consumer wearable technologies have wide applications, including some that have US Food and Drug Administration clearance for health-related notifications. While wearable technologies may have premarket testing, validation, and safety evaluation as part of a regulatory authorization process, information on their postmarket use remains limited. The Stanford Center for Digital Health organized 2 pan-stakeholder think tank meetings to develop an organizing concept for empirical research on the postmarket evaluation of consumer-facing wearables.
View Article and Find Full Text PDFClin Appl Thromb Hemost
September 2025
Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China.
Hemophilia, an X-linked monogenic disorder, arises from mutations in the or genes, which encode clotting factor VIII (FVIII) or clotting factor IX (FIX), respectively. As a prominent hereditary coagulation disorder, hemophilia is clinically manifested by spontaneous hemorrhagic episodes. Severe cases may progress to complications such as stroke and arthropathy, significantly compromising patients' quality of life.
View Article and Find Full Text PDFTissue Eng Regen Med
September 2025
Department of Joint and Sports Medicine, Chaoyang Central Hospital, Chaoyang City, Liaoning Province, China.
Background: Osteoarthritis (OA) represents a major global health challenge with no ideal treatment options available. Early-stage treatment typically focuses on symptomatic relief of pain and stiffness; while late-stage patients can only opt for surgical interventions such as joint replacement to improve quality of life. Cell-free therapy based on extracellular vesicles (EVs) has offered a novel therapeutic approach for regulating bone metabolism and repairing cartilage, demonstrating emerging potential.
View Article and Find Full Text PDFMed Oncol
September 2025
Department of Biotechnology, Institute of Engineering and Management, University of Engineering and Management, Kolkata, Kolkata, India.
Oligomeric proanthocyanidins (OPCs), condensed tannins found plentiful in grape seeds and berries, have higher bioavailability and therapeutic benefits due to their low degree of polymerization. Recent evidence places OPCs as effective modulators of cancer stem cell (CSC) plasticity and tumor growth. Mechanistically, OPCs orchestrate multi-pathway inhibition by destabilizing Wnt/β-catenin, Notch, PI3K/Akt/mTOR, JAK/STAT3, and Hedgehog pathways, triggering β-catenin degradation, silencing stemness regulators (OCT4, NANOG, SOX2), and stimulating tumor-suppressive microRNAs (miR-200, miR-34a).
View Article and Find Full Text PDFJ Drug Target
September 2025
Department of Pharmacology, Rajarshi Shahu College of Pharmacy, Buldana, Maharashtra, INDIA.
Natural phytoconstituents such as betanin and curcumin have attracted interest for their significant antioxidant and anti-inflammatory properties. Their therapeutic efficacy is notably constrained by inadequate bioavailability and reduced skin permeability. The current study developed an ethosome-based gel system for the delivery of betanin and curcumin, with the objective of improving transdermal penetration and providing sustained anti-inflammatory effects.
View Article and Find Full Text PDF